MGFA Nancy Law Impact Award Grant

MGFA Nancy Law Impact Award Grant

Status: ACTIVE
Funder: Myasthenia Gravis Foundation of America
Amount: Up to US $300,000
Last Updated: December 09, 2025

Summary

The MGFA Nancy Law Impact Award supports high-impact clinical research and innovative scientific investigations aimed at improving treatment paradigms for Myasthenia Gravis (MG). Established in honor of Nancy Law, this award seeks to fund projects that enhance patient outcomes through rigorous research. With a maximum funding of $300,000 over three years, the award encourages proposals addressing key research priorities, including disease mechanisms and therapeutic strategies, while promoting collaboration among investigators globally.

Overview

Myasthenia Gravis Research Foundation Our Vision: A World Without MG Our Mission: Create Connections, Enhance Lives, Improve Care, Cure MG Clinician and scientist investigators are engaged in groundbreaking myasthenia research all over the world. MGFA funds promising research studies and clinical trials to discover potential new treatments and methods of living a better quality of life with MG. Nancy Law Impact Award This award was created in honor of Nancy Law, the former CEO and board chair of the Myasthenia Gravis Foundation of America. Her dedication to supporting people with MG inspired this research funding award opportunity. The Nancy Law Impact Award supports high-impact clinical research or scientific investigations that are focused and innovative. High-impact clinical research proposals should focus on patient outcome measurements or alteration in clinical or research practices which improve present treatment paradigms. Scientific projects require a clear plan that will lead to new competitive federal or private foundation supported investigations. Research Priorities The research committee has identified five broad research priorities of unmet need in the field of neuromuscular junction disorders: BiomarkersDisease MechanismsTherapeutic strategiesImproving patient outcomesPediatric treatment strategies, safety concerns, and long-term outcome Though this research agenda is intended to guide researchers towards topics that are important to the MGFA, the research committee will accept proposals outside of these priority areas and is committed to supporting the best science. Funding MGFA will fund highly meritorious projects with a maximum of $300,000 over three years, of which no more than 10% may be allocated to indirect costs.

Eligibility

You can learn more about this opportunity by visiting the funder's website. The RFA is open to established mid and senior-level investigators with faculty status.Applications in all areas of MG research will be accepted from U.S. and international applicants.

Ineligibility

This RFA is not open to for-profit (i.e. biotechnology, pharmaceutical, etc.) applicants.